Statistically significant linear increase in use of psychostimulants and nootropic drugs, anxiolytics, sedatives and hypnotics, gabapentinoids during the observed time period. by Jelena Filimonovic (22305307)

Subjects:

Expression levels of SACMV DNA-A and DNA-B encoded virulence factors in TME3 and T200 at 12, 32 and 67dpi measured by RT-qPCR. by Bulelani L. Sizani (21485746)

Subjects:

Structure-based alignment and homology modelling of MeTIR domains. by Bulelani L. Sizani (21485746)

Subjects:

Primers used for SACMV DNA-A and DNA-B virulence proteins and PacBio SMRT sequence of NLR and LRR-PK/PL genes. by Bulelani L. Sizani (21485746)

Subjects:

Expression profile of WRKY-TFs and ROS accumulation in susceptible T200 and tolerant TME3 cassava genotypes. by Bulelani L. Sizani (21485746)

Subjects:

Transcript levels of MAPK, NIK, NLR and SA-depended gene pathways and responsive genes. by Bulelani L. Sizani (21485746)

Subjects:

South African cassava mosaic virus (SACMV) genome structure and the effect of SACMV on cassava leaf symptoms. by Bulelani L. Sizani (21485746)

Subjects:

Transcript levels of MAPK, NIK, NLR and SA-dependent gene pathways and responsive genes. by Bulelani L. Sizani (21485746)

Subjects:

Differentially-expressed NLR genes in susceptible T200 and tolerant TME3 genotypes infected with SACMV. by Bulelani L. Sizani (21485746)

Subjects:

Total count of HiFi reads indicating gene variation in 24 cassava genotypes. by Bulelani L. Sizani (21485746)

Subjects:

Hypothetical model of the molecular mechanism underlying the ability of SACMV to suppress the host RNA silencing mechanism (PTGS) and systemic acquired resistance (SAR). by Bulelani L. Sizani (21485746)

Subjects:

Characteristics of HACE respondents by year. by David Henderson (4612354)

Subjects:

Details of the GWAS data in this study. by Jing Wang (6206297)

Subjects:

Map with color coding showing the relative risk of loss at the regional level for each country in Sub-Saharan Africa. by Beatrice T. Nganso (4114768)

Subjects:

Group control-after intervention. by Nan Tang (642590)

Subjects:

Group SFA-before intervention. by Nan Tang (642590)

Subjects:

Lost cases. by Nan Tang (642590)

Subjects:

Group control-before intervention. by Nan Tang (642590)

Subjects:

Patient satisfaction with SFA intervention(%). by Nan Tang (642590)

Subjects:

Pre-Experiment. by Nan Tang (642590)

Subjects: